{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:24:14Z","timestamp":1779200654734,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20492-x","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:08:05Z","timestamp":1760713685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RHOBTB2 enhances cell proliferation of acute myeloid leukemia by modulating Hippo-YAP1 signaling and dependent of KLHL13"],"prefix":"10.1038","volume":"15","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"20492_CR1","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry, M. Z. et al. A review of treatment options employed in relapsed\/refractory AML. Hematology (Amsterdam Netherlands). 28, 2196482. https:\/\/doi.org\/10.1080\/16078454.2023.2196482 (2023).","journal-title":"Hematology (Amsterdam Netherlands)"},{"key":"20492_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol, F., D\u00f6hner, H. & Ganser, A. How I treat refractory and relapsed acute myeloid leukemia. Blood 143, 11\u201320. https:\/\/doi.org\/10.1182\/blood.2023022481 (2024).","journal-title":"Blood"},{"key":"20492_CR3","doi-asserted-by":"publisher","unstructured":"Liu, H. Emerging agents and regimens for AML. J. Hematol. Oncol. 14 https:\/\/doi.org\/10.1186\/s13045-021-01062-w (2021).","DOI":"10.1186\/s13045-021-01062-w"},{"key":"20492_CR4","doi-asserted-by":"publisher","unstructured":"Bose, P., Vachhani, P. & Cortes, J. E. Treatment of relapsed\/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 18 https:\/\/doi.org\/10.1007\/s11864-017-0456-2 (2017).","DOI":"10.1007\/s11864-017-0456-2"},{"key":"20492_CR5","doi-asserted-by":"publisher","unstructured":"Ji, W. & Rivero, F. Atypical Rho GTPases of the RhoBTB subfamily: Roles in vesicle trafficking and tumorigenesis. Cells 5 https:\/\/doi.org\/10.3390\/cells5020028 (2016).","DOI":"10.3390\/cells5020028"},{"key":"20492_CR6","doi-asserted-by":"publisher","unstructured":"Kim, K., Kim, D. G. & Kim, Y. J. RhoBTB3 functions as a novel regulator of autophagy by suppressing AMBRA1 stability. Cells 13 https:\/\/doi.org\/10.3390\/cells13191659 (2024).","DOI":"10.3390\/cells13191659"},{"key":"20492_CR7","doi-asserted-by":"publisher","first-page":"e1539","DOI":"10.1212\/wnl.0000000000011543","volume":"96","author":"S Zagaglia","year":"2021","unstructured":"Zagaglia, S. et al. RHOBTB2 mutations expand the phenotypic spectrum of alternating hemiplegia of childhood. Neurology 96, e1539\u2013e1550. https:\/\/doi.org\/10.1212\/wnl.0000000000011543 (2021).","journal-title":"Neurology"},{"key":"20492_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/humu.23550","volume":"39","author":"H Belal","year":"2018","unstructured":"Belal, H. et al. De Novo variants in RHOBTB2, an atypical Rho GTPase gene, cause epileptic encephalopathy. Hum. Mutat. 39, 1070\u20131075. https:\/\/doi.org\/10.1002\/humu.23550 (2018).","journal-title":"Hum. Mutat."},{"key":"20492_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrurol.2017.184","volume":"15","author":"SL Woldu","year":"2018","unstructured":"Woldu, S. L., Hutchinson, R. C., Krabbe, L. M., Sanli, O. & Margulis, V. The Rho GTPase signalling pathway in urothelial carcinoma. Nat. Rev. Urol. 15, 83\u201391. https:\/\/doi.org\/10.1038\/nrurol.2017.184 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"20492_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2174\/092986709787846569","volume":"16","author":"Q Lu","year":"2009","unstructured":"Lu, Q., Longo, F. M., Zhou, H., Massa, S. M. & Chen, Y. H. Signaling through Rho GTPase pathway as viable drug target. Curr. Med. Chem. 16, 1355\u20131365. https:\/\/doi.org\/10.2174\/092986709787846569 (2009).","journal-title":"Curr. Med. Chem."},{"key":"20492_CR11","doi-asserted-by":"publisher","first-page":"15269","DOI":"10.18632\/aging.203087","volume":"13","author":"P Liu","year":"2021","unstructured":"Liu, P., Ma, Q., Chen, H., Zhang, L. & Zhang, X. Identification of RHOBTB2 aberration as an independent prognostic indicator in acute myeloid leukemia. Aging (Albany NY). 13, 15269\u201315284. https:\/\/doi.org\/10.18632\/aging.203087 (2021).","journal-title":"Aging (Albany NY)"},{"key":"20492_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.21037\/tcr-22-2500","volume":"12","author":"XH Sun","year":"2023","unstructured":"Sun, X. H. et al. Identifying a prognostic model and screening of potential natural compounds for acute myeloid leukemia. Transl. Cancer Res. 12, 1535\u20131551. https:\/\/doi.org\/10.21037\/tcr-22-2500 (2023).","journal-title":"Transl. Cancer Res."},{"key":"20492_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo, S., Dupont, S. & Cordenonsi, M. The biology of YAP\/TAZ: Hippo signaling and beyond. Physiol. Rev. 94, 1287\u20131312. https:\/\/doi.org\/10.1152\/physrev.00005.2014 (2014).","journal-title":"Physiol. Rev."},{"key":"20492_CR14","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1002\/mco2.340","volume":"4","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. YAP\/TAZ: Molecular pathway and disease therapy. MedComm 4, e340. https:\/\/doi.org\/10.1002\/mco2.340 (2023).","journal-title":"MedComm"},{"key":"20492_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"Moya, I. M. & Halder, G. Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol. 20, 211\u2013226. https:\/\/doi.org\/10.1038\/s41580-018-0086-y (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"20492_CR16","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1007\/s11033-023-08329-0","volume":"50","author":"J Zhu","year":"2023","unstructured":"Zhu, J., Wu, T. & Lin, Q. Non-hippo kinases: Indispensable roles in YAP\/TAZ signaling and implications in cancer therapy. Mol. Biol. Rep. 50, 4565\u20134578. https:\/\/doi.org\/10.1007\/s11033-023-08329-0 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"20492_CR17","doi-asserted-by":"publisher","first-page":"1173491","DOI":"10.3389\/fcell.2023.1173491","volume":"11","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Gene SH3BGRL3 regulates acute myeloid leukemia progression through circRNA_0010984 based on competitive endogenous RNA mechanism. Front. cell. Dev. Biol.. 11, 1173491. https:\/\/doi.org\/10.3389\/fcell.2023.1173491 (2023).","journal-title":"Front. cell. Dev. Biol."},{"key":"20492_CR18","doi-asserted-by":"publisher","first-page":"e3404","DOI":"10.1002\/jgm.3404","volume":"24","author":"N Wang","year":"2022","unstructured":"Wang, N. et al. Circular RNA circ_0040823 inhibits the proliferation of acute myeloid leukemia cells and induces apoptosis by regulating miR-516b\/PTEN. J. Gene. Med. 24, e3404. https:\/\/doi.org\/10.1002\/jgm.3404 (2022).","journal-title":"J. Gene. Med."},{"key":"20492_CR19","doi-asserted-by":"publisher","first-page":"842214","DOI":"10.3389\/fcell.2022.842214","volume":"10","author":"P Feng","year":"2022","unstructured":"Feng, P. et al. Deacetylation of YAP1 promotes the resistance to Chemo- and targeted therapy in FLT3-ITD(+) AML cells. Front. cell. Dev. Biol.. 10, 842214. https:\/\/doi.org\/10.3389\/fcell.2022.842214 (2022).","journal-title":"Front. cell. Dev. Biol."},{"key":"20492_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2174\/1389201023666220617150346","volume":"24","author":"Y Song","year":"2023","unstructured":"Song, Y., Chen, X., Huang, R. & Liu, J. Dysregulated YAP1\/Hippo pathway contributes to doxorubicin (ADM) resistance in acute myeloid leukemia (AML). Curr. Pharm. Biotechnol. 24, 676\u2013685. https:\/\/doi.org\/10.2174\/1389201023666220617150346 (2023).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"20492_CR21","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013w560. https:\/\/doi.org\/10.1093\/nar\/gkz430 (2019).","journal-title":"Nucleic Acids Res."},{"key":"20492_CR22","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98\u2013w102. https:\/\/doi.org\/10.1093\/nar\/gkx247 (2017).","journal-title":"Nucleic Acids Res."},{"key":"20492_CR23","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"D Szklarczyk","year":"2011","unstructured":"Szklarczyk, D. et al. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561\u2013568. https:\/\/doi.org\/10.1093\/nar\/gkq973 (2011).","journal-title":"Nucleic Acids Res."},{"key":"20492_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jprot.2017.08.002","volume":"171","author":"KTB Crosara","year":"2018","unstructured":"Crosara, K. T. B., Moffa, E. B., Xiao, Y. & Siqueira, W. L. Merging in-silico and in vitro salivary protein complex partners using the STRING database: A tutorial. J. Proteom. 171, 87\u201394. https:\/\/doi.org\/10.1016\/j.jprot.2017.08.002 (2018).","journal-title":"J. Proteom."},{"key":"20492_CR25","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1038\/onc.2016.441","volume":"36","author":"YM Choi","year":"2017","unstructured":"Choi, Y. M. et al. DBC2\/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer. Oncogene 36, 2802\u20132812. https:\/\/doi.org\/10.1038\/onc.2016.441 (2017).","journal-title":"Oncogene"},{"key":"20492_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mc.20598","volume":"49","author":"H Mao","year":"2010","unstructured":"Mao, H. et al. A novel tumor suppressor gene RhoBTB2 (DBC2): Frequent loss of expression in sporadic breast cancer. Mol. Carcinog. 49, 283\u2013289. https:\/\/doi.org\/10.1002\/mc.20598 (2010).","journal-title":"Mol. Carcinog."},{"key":"20492_CR27","doi-asserted-by":"publisher","unstructured":"Chircop, M. Rho GTPases as regulators of mitosis and cytokinesis in mammalian cells. Small GTPases. 5 https:\/\/doi.org\/10.4161\/sgtp.29770 (2014).","DOI":"10.4161\/sgtp.29770"},{"key":"20492_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1745-7254.2008.00773.x","volume":"29","author":"J Berthold","year":"2008","unstructured":"Berthold, J., Schenkova, K. & Rivero, F. Rho GTPases of the RhoBTB subfamily and tumorigenesis. Acta Pharmacol. Sin. 29, 285\u2013295. https:\/\/doi.org\/10.1111\/j.1745-7254.2008.00773.x (2008).","journal-title":"Acta Pharmacol. Sin"},{"key":"20492_CR29","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1074\/jbc.M705986200","volume":"283","author":"SN Freeman","year":"2008","unstructured":"Freeman, S. N., Ma, Y. & Cress, W. D. RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J. Biol. Chem. 283, 2353\u20132362. https:\/\/doi.org\/10.1074\/jbc.M705986200 (2008).","journal-title":"J. Biol. Chem."},{"key":"20492_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.gene.2011.07.018","volume":"486","author":"H Mao","year":"2011","unstructured":"Mao, H. et al. RhoBTB2 (DBC2) functions as tumor suppressor via inhibiting proliferation, preventing colony formation and inducing apoptosis in breast cancer cells. Gene 486, 74\u201380. https:\/\/doi.org\/10.1016\/j.gene.2011.07.018 (2011).","journal-title":"Gene"},{"key":"20492_CR31","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/mdc3.13880","volume":"10","author":"P de Baena","year":"2023","unstructured":"de Baena, P. Exploring the spectrum of RHOBTB2 variants associated with developmental encephalopathy 64: A case series and literature review. Mov. Disord. Clin. Pract. 10, 1671\u20131679. https:\/\/doi.org\/10.1002\/mdc3.13880 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"20492_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/s-0040-1722288","volume":"12","author":"J Fonseca","year":"2023","unstructured":"Fonseca, J. et al. RHOBTB2 p.Arg511Trp mutation in early infantile epileptic Encephalopathy-64: Review and case report. J. Pediatr. Genet. 12, 155\u2013158. https:\/\/doi.org\/10.1055\/s-0040-1722288 (2023).","journal-title":"J. Pediatr. Genet."},{"key":"20492_CR33","doi-asserted-by":"publisher","first-page":"105616","DOI":"10.1016\/j.phrs.2021.105616","volume":"169","author":"S Xiang","year":"2021","unstructured":"Xiang, S. et al. Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy. Pharmacol. Res. 169, 105616. https:\/\/doi.org\/10.1016\/j.phrs.2021.105616 (2021).","journal-title":"Pharmacol. Res."},{"key":"20492_CR34","doi-asserted-by":"publisher","first-page":"116270","DOI":"10.1016\/j.ejmech.2024.116270","volume":"269","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Targeting kelch-like (KLHL) proteins: Achievements, challenges and perspectives. Eur. J. Med. Chem. 269, 116270. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116270 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"20492_CR35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.devcel.2007.03.019","volume":"12","author":"I Sumara","year":"2007","unstructured":"Sumara, I. et al. A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating mitotic progression and completion of cytokinesis in human cells. Dev. Cell. 12, 887\u2013900. https:\/\/doi.org\/10.1016\/j.devcel.2007.03.019 (2007).","journal-title":"Dev. Cell"},{"key":"20492_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1083\/jcb.200906117","volume":"187","author":"S Maerki","year":"2009","unstructured":"Maerki, S. et al. The Cul3-KLHL21 E3 ubiquitin ligase targets Aurora B to midzone microtubules in anaphase and is required for cytokinesis. J. Cell Biol. 187, 791\u2013800. https:\/\/doi.org\/10.1083\/jcb.200906117 (2009).","journal-title":"J. Cell Biol."},{"key":"20492_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/ijc.34249","volume":"152","author":"CW Mui","year":"2023","unstructured":"Mui, C. W. et al. Targeting YAP1\/TAZ in nonsmall-cell lung carcinoma: From molecular mechanisms to precision medicine. Int. J. Cancer. 152, 558\u2013571. https:\/\/doi.org\/10.1002\/ijc.34249 (2023).","journal-title":"Int. J. Cancer"},{"key":"20492_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cac2.12417","volume":"43","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer. Cancer Commun. (London England). 43, 582\u2013612. https:\/\/doi.org\/10.1002\/cac2.12417 (2023).","journal-title":"Cancer Commun. (London England)"},{"key":"20492_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2022.07.298","volume":"112-113","author":"J Cao","year":"2022","unstructured":"Cao, J., Huang, S. & Li, X. Rapamycin inhibits the progression of human acute myeloid leukemia by regulating the circ_0094100\/miR-217\/ATP1B1 axis. Exp. Hematol. 112-113, 60\u201369e62. https:\/\/doi.org\/10.1016\/j.exphem.2022.07.298 (2022).","journal-title":"Exp. Hematol."},{"key":"20492_CR40","doi-asserted-by":"publisher","first-page":"2240133","DOI":"10.1080\/16078454.2023.2240133","volume":"28","author":"W Wu","year":"2023","unstructured":"Wu, W. et al. Circ_0001602 aggravates the progression of acute myeloid leukemia by regulating the miR-192-5p\/ZBTB20 axis. Hematology (Amsterdam Netherlands). 28, 2240133. https:\/\/doi.org\/10.1080\/16078454.2023.2240133 (2023).","journal-title":"Hematology (Amsterdam Netherlands)"},{"key":"20492_CR41","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.2147\/ijn.S407116","volume":"18","author":"F Chao","year":"2023","unstructured":"Chao, F. et al. Extracellular vesicles derived circSH3PXD2A inhibits chemoresistance of small cell lung cancer by miR-375-3p\/YAP1. Int. J. Nanomed. 18, 2989\u20133006. https:\/\/doi.org\/10.2147\/ijn.S407116 (2023).","journal-title":"Int. J. Nanomed."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20492-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:08:06Z","timestamp":1760713686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20492-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20492"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20492-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36428"}}